<table id="table6" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies [see<linkhtml href="#S12.3"> Clinical Pharmacology (12.3) </linkhtml>(<linkhtml href="#table12">Tables 12 </linkhtml>and<linkhtml href="#table13"> 13</linkhtml>) for magnitude of interaction]</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr stylecode="Botrule">
<th stylecode="Lrule Rrule">Concomitant Drug Class:<br/>Drug Name</th>
<th stylecode="Rrule">Effect on<br/>Concentration</th>
<th stylecode="Rrule">Clinical Comment</th>
</tr>
<tr stylecode="Botrule">
<th align="center" colspan="3" stylecode="Lrule Rrule">HIV Antiviral Agents: Reverse Transcriptase Inhibitors</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Delavirdine</td>
<td stylecode="Rrule">↑ nelfinavir (C<sub>min</sub>)<br/>↓ delavirdine</td>
<td stylecode="Rrule">Concentrations of nelfinavir were increased while concentrations of delavirdine were decreased when the two agents were coadministered. Appropriate doses of the combination, with respect to safety and efficacy, have not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Nevirapine</td>
<td stylecode="Rrule">↓ nelfinavir (C<sub>min</sub>)</td>
<td stylecode="Rrule">Concentrations of nelfinavir were decreased when coadministered with nevirapine. An appropriate dose of nelfinavir with respect to safety and efficacy has not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Didanosine</td>
<td stylecode="Rrule">↔ nelfinavir</td>
<td stylecode="Rrule">There was no change in nelfinavir concentration when coadministered with didanosine. However, it is recommended that didanosine be administered on an empty stomach; therefore, didanosine should be given one hour before or two hours after VIRACEPT (given with food).</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV Antiviral Agents: Protease Inhibitors</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Indinavir</td>
<td stylecode="Rrule">↑ nelfinavir<br/>↑ indinavir</td>
<td stylecode="Rrule">Concentrations of both indinavir and nelfinavir were increased when the two agents were coadministered. Appropriate doses for these combinations, with respect to safety and efficacy, have not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ritonavir</td>
<td stylecode="Rrule">↑ nelfinavir<br/>↔ ritonavir</td>
<td stylecode="Rrule">Concentrations of nelfinavir were increased when coadministered with ritonavir. An appropriate dose of nelfinavir for this combination, with respect to safety and efficacy, has not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Saquinavir</td>
<td stylecode="Rrule">↑ nelfinavir<br/>↑ saquinavir</td>
<td stylecode="Rrule">Concentrations of both saquinavir and nelfinavir were increased when the two agents were coadministered. Appropriate doses for these combinations, with respect to safety and efficacy, have not been established.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTICOAGULANT</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Warfarin</td>
<td stylecode="Rrule">Warfarin</td>
<td stylecode="Rrule">Coadministration of warfarin and VIRACEPT may affect concentrations of warfarin. It is recommended that the INR (international normalized ratio) be monitored carefully during treatment with VIRACEPT, especially when commencing therapy.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTICONVULSANTS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Carbamazepine Phenobarbital<br/>Phenytoin</td>
<td stylecode="Rrule">
<br/>↓ nelfinavir<br/>
<br/>↓ phenytoin</td>
<td stylecode="Rrule">Concentrations of nelfinavir may be decreased. VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly.<br/>Phenytoin plasma/serum concentrations should be monitored; phenytoin dose may require adjustment to compensate for altered phenytoin concentration.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIDEPRESSANT</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Trazodone</td>
<td stylecode="Rrule">↑ trazodone</td>
<td stylecode="Rrule">Concomitant use of trazodone and VIRACEPT may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as VIRACEPT, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIGOUT</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Colchicine</td>
<td stylecode="Rrule">↑ colchicines</td>
<td stylecode="Rrule">Patients with renal or hepatic impairment should not be given colchicine with VIRACEPT due to the risk of colchicine toxicity.<br/>
<br/>Treatment of gout flares –<br/>co- administration of colchicine in patients on VIRACEPT:<br/>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.<br/>
<br/>Prophylaxis of gout-flares –<br/>coadministration of colchicine in patients on VIRACEPT:<br/>
<br/>
<br/>If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<br/>Treatment of familial Mediterranean fever (FMF)– coadministration of colchicine in patients on VIRACEPT:<br/>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIMYCOBACTERIAL</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifabutin</td>
<td stylecode="Rrule">↑ rifabutin<br/>↓ nelfinavir<br/>  (750 mg TID)<br/>↔ nelfinavir<br/>  (1250 mg BID)</td>
<td stylecode="Rrule">It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT; 1250 mg BID is the preferred dose of VIRACEPT when coadministered with rifabutin.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ENDOTHELIN RECEPTOR ANTAGONIST</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Bosentan</td>
<td stylecode="Rrule">↑ bosentan</td>
<td stylecode="Rrule">Concentrations of bosentan may be increased when coadministered with VIRACEPT. Coadministration of bosentan in patients on VIRACEPT or coadministration of VIRACEPT in patients on bosentan:<br/>Start at or adjust bosentan to 62.5 mg once daily or every other day based upon individual tolerability.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA REDUCTASE INHIBITORS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Atorvastatin<br/>Rosuvastatin</td>
<td stylecode="Rrule">↑ atorvastatin<br/>↑ rosuvastatin</td>
<td stylecode="Rrule">Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 40 mg/day.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">IMMUNOSUPPRESSANTS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cyclosporine<br/>Tacrolimus<br/>Sirolimus</td>
<td stylecode="Rrule">↑ immuno-suppressants<br/>↑ nelfinavir</td>
<td stylecode="Rrule">Concentrations of these immunosuppressants and nelfinavir may be increased by coadministration of these agents with nelfinavir.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">INHALED BETA AGONIST</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Salmeterol</td>
<td stylecode="Rrule">↑ salmeterol</td>
<td stylecode="Rrule">Concurrent administration of salmeterol with VIRACEPT is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">INHALED/NASAL STEROID</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fluticasone</td>
<td stylecode="Rrule">↑ fluticasone</td>
<td stylecode="Rrule">Concomitant use of fluticasone propionate and VIRACEPT may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">MACROLIDE ANTIBIOTIC</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Azithromycin</td>
<td stylecode="Rrule">↑ azithromycin</td>
<td stylecode="Rrule">Dose adjustment of azithromycin is not recommended, but close monitoring for known side effects such as liver enzyme abnormalities and hearing impairment is warranted.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">NARCOTIC ANALGESIC</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Methadone</td>
<td stylecode="Rrule">↓ methadone</td>
<td stylecode="Rrule">Concentrations of methadone were decreased when coadministered with VIRACEPT. Dosage of methadone may need to be increased when coadministered with VIRACEPT.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HORMONAL CONTRACEPTIVES</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ethinyl estradiol<br/>Norethindrone</td>
<td stylecode="Rrule">↓ ethinyl estradiol<br/>↓ norethindrone</td>
<td stylecode="Rrule">Concentrations of ethinyl estradiol and norethindrone were decreased when coadministered with VIRACEPT. Alternative or additional contraceptive measures should be used when oral contraceptives containing ethinyl estradiol or norethindrone and VIRACEPT are coadministered.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">PDE5 INHIBITORS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sildenafil<br/>Vardenafil<br/>Tadalafil</td>
<td stylecode="Rrule">↑ PDE5 Inhibitors</td>
<td stylecode="Rrule">Concomitant use of PDE5 inhibitors and VIRACEPT should be undertaken with caution.<br/>
<br/>May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.<br/>
<br/>
<content stylecode="underline">Use of PDE5 inhibitors for pulmonary arterial hypertension (PAH):</content>
<br/>
<br/>• Use of sildenafil (REVATIO) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) <content stylecode="italics">[see<linkhtml href="#S4"> Contraindications (4)</linkhtml>]</content>.<br/>
<br/>• The following dose adjustments are recommended for use of tadalafil (ADCIRCA™) with VIRACEPT:<br/>
<br/>
<content stylecode="underline">Coadministration of ADCIRCA in patients on VIRACEPT or coadministration of VIRACEPT in patients on ADCIRCA:</content>
<br/>
<br/>Start at or adjust ADCIRCA to 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">Use of PDE5 inhibitors for erectile dysfunction:</content>
<br/>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 24 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours, is recommended. Use with increased monitoring for adverse events.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">PROTON PUMP INHIBITORS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Omeprazole</td>
<td stylecode="Rrule">↓ nelfinavir</td>
<td stylecode="Rrule">Omeprazole decreases the plasma concentrations of nelfinavir. Concomitant use of proton pump inhibitors and VIRACEPT may lead to a loss of virologic response and development of resistance.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIPSYCHOTICS</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Quetiapine</td>
<td stylecode="Rrule">↑ quetiapine</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of VIRACEPT in patients taking quetiapine:</content>
<br/>Consider alternative antiretroviral therapy to avoid increases in quetiapine drug exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring. <br/>
<content stylecode="underline">Initiation of quetiapine in patients taking VIRACEPT:</content>
<br/>Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</td>
</tr>
</tbody>
</table>